Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mammaglobin a: a promising marker for breast cancer.
O'Brien N, Maguire TM, O'Donovan N, Lynch N, Hill AD, McDermott E, O'Higgins N, Duffy MJ. O'Brien N, et al. Clin Chem. 2002 Aug;48(8):1362-4. Clin Chem. 2002. PMID: 12142396 No abstract available.
HER-2 signaling and inhibition in breast cancer.
Browne BC, O'Brien N, Duffy MJ, Crown J, O'Donovan N. Browne BC, et al. Curr Cancer Drug Targets. 2009 May;9(3):419-38. doi: 10.2174/156800909788166484. Curr Cancer Drug Targets. 2009. PMID: 19442060 Review.
Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer.
Canonici A, Gijsen M, Mullooly M, Bennett R, Bouguern N, Pedersen K, O'Brien NA, Roxanis I, Li JL, Bridge E, Finn R, Siamon D, McGowan P, Duffy MJ, O'Donovan N, Crown J, Kong A. Canonici A, et al. Oncotarget. 2013 Oct;4(10):1592-605. doi: 10.18632/oncotarget.1148. Oncotarget. 2013. PMID: 24009064 Free PMC article.
PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.
McDermott MS, Browne BC, Conlon NT, O'Brien NA, Slamon DJ, Henry M, Meleady P, Clynes M, Dowling P, Crown J, O'Donovan N. McDermott MS, et al. Mol Cancer. 2014 Jun 24;13:157. doi: 10.1186/1476-4598-13-157. Mol Cancer. 2014. PMID: 24958351 Free PMC article.
42 results